Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$0.04.
- Arbutus Biopharma's EPS (Weighted Average and Diluted) rose 6000.0% to -$0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.23, marking a year-over-year increase of 4651.16%. This contributed to the annual value of -$0.38 for FY2024, which is 1438.5% up from last year.
- Latest data reveals that Arbutus Biopharma reported EPS (Weighted Average and Diluted) of -$0.04 as of Q3 2025, which was up 6000.0% from $0.01 recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q2 2025 and a low of -$0.24 during Q3 2021
- For the 5-year period, Arbutus Biopharma's EPS (Weighted Average and Diluted) averaged around -$0.12, with its median value being -$0.11 (2022).
- Data for Arbutus Biopharma's EPS (Weighted Average and Diluted) shows a peak YoY increase of 10909.09% (in 2025) and a maximum YoY decrease of 3000.0% (in 2025) over the last 5 years.
- Over the past 5 years, Arbutus Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.15 in 2021, then grew by 6.67% to -$0.14 in 2022, then rose by 14.29% to -$0.12 in 2023, then soared by 43.88% to -$0.07 in 2024, then skyrocketed by 40.6% to -$0.04 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.04 in Q3 2025, compared to $0.01 in Q2 2025 and -$0.13 in Q1 2025.